Table 1: Examples of antiangiogenic agents in clinical trial for patients with high grade glioma.


ABT-510Thrombospondin-1 mimetic peptideCD36 receptor
AMG 102Monoclonal antibodyHGF/SF
AfliberceptSoluble decoy receptorVEGF-A,B, PlGF
BevacizumabMonoclonal antibodyVEGF-A
BrivanibTyrosine kinase inhibitorFGFR, VEGFR2
CediranibTyrosine kinase inhibitorVEGFR1–3, PDGFRβ, c-Kit
CilengitideRGD synthetic peptideIntegrins αvβ3, αvβ5
CT-322Fibronectin (adnectin)-based inhibitorVEGFR1–3
DasatinibTyrosine kinase inhibitorPDGFRβ, Src, BCR-ABL, c-Kit, EphA2
ImatinibTyrosine kinase inhibitorPDGFRβ, BCR-ABL, c-Kit
LenalidomideImmunomodulatory and anti-inflammatoryFGF pathway
Pazopanib (GW786034)Tyrosine kinase inhibitorVEGFR1–3, PDGFRβ, c-Kit
SorafenibTyrosine kinase inhibitorVEGFR2,3, BRAF, PDGFRβ, c-Kit, Ras, p38α
SunitinibTyrosine kinase inhibitorVEGFR2, PDGFRβ, Flt3, c-Kit
Tandutinib (MLN518)Tyrosine kinase inhibitorPDGFRβ, Flt3, c-Kit
Vandetanib (ZD6474)Tyrosine kinase inhibitorVEGFR2, EGFR, RET
Vatalanib (PTK787)Tyrosine kinase inhibitorVEGFR1–3, PDGFRβ, c-Kit
XL-184Tyrosine kinase inhibitorVEGFR2, Met, RET, c-Kit, Flt3, Tie-2

A more complete listing of anti-angiogenic agents in clinical trials for patients with high grade gliomas can be found at the National Institutes of Health website when searching for “glioma, brain cancer, glioblastoma, and angiogenesis”.